Pharma BD Deal Intelligence
A defensive merger of two struggling biotechs that fixed nothing — Xenova collapsed in value and was sold off for a fraction of the combined companies' worth four years later, with the flagship legacy asset (TA-CD) later failing Phase III
Full analysis, sources & comparables →Xenova offers £123.7M (~$179.7M) all-stock for Cantab to combine small-molecule oncology with therapeutic vaccine platform.
Post-merger, Xenova licenses TA-CIN to Cancer Research Technology, signaling de-prioritization of the HPV therapeutic vaccine internally.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
All-stock UK biotech merger; £34M ($51M) at headline, ~$179M reported in BioWorld archive (likely combined enterprise value). Oncology small molecules + therapeutic vaccines.
A defensive merger of two struggling biotechs that fixed nothing — Xenova collapsed in value and was sold off for a fraction of the combined companies' worth four years later, with the flagship legacy asset (TA-CD) later failing Phase III
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Xenova Group plc / Cantab Pharmaceuticals plc (UK) (this deal) | 2001 | $179M | 16 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals